<DOC>
	<DOCNO>NCT01225965</DOCNO>
	<brief_summary>To investigate physical inflammation inhibition effect EIL ( Ectoin-Hydro-Complex ) subject establish SALIA-cohort preventive effect lung function decline .</brief_summary>
	<brief_title>Efficacy Feasibility EctoinÂ® Inhalation Solution Inflammatory Obstruction Ageing Lung</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Postmenopausal female ( 75 80 year ) FEV1/FVC &lt; 0,77 ( investigation 2007/2008 ) Inflammatory marker TFNalpha &gt; median neutrophilic granulocyte &gt; median ( investigation 2007/2008 ) Non smoker ex smoker stop smoke longer 6 month Participation another clinical study previous month Severe concomitant disease may impact study participation Hypersensitivity Ectoin Myocardial infarction apoplexy within last year Uncontrolled hypertension : systolic blood pressure &gt; 200 mmHg diastolic pressure &gt; 120 mmHg Known aortic aneurysm Other respiratory disease ( e.g . cystic fibrosis , alpha1Antitrypsin deficiency , sarcoidosis , allergic alveolitis , tuberculosis , etc . ) Patients treatment live attenuate vaccination within 14 day prior screen visit ( Inactivated influenza vaccination acceptable , provide administer within 7 day prior screen visit ) investigator decision</criteria>
	<gender>Female</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Particulate Matter induce inflammation lung</keyword>
</DOC>